Incyte Corp traded at $74.17 this Wednesday May 18th, decreasing $1.34 or 1.77 percent since the previous trading session. Looking back, over the last four weeks, Incyte Corp lost 6.67 percent. Over the last 12 months, its price fell by 9.23 percent. Looking ahead, we forecast Incyte Corp to be priced at 73.07 by the end of this quarter and at 67.95 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
74.08
Daily Change
-1.89%
Yearly
-9.34%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 16.91 0.31 1.84% -20.37%
Agenus 1.59 0.01 0.63% -51.23%
Agios Pharmaceuticals 22.30 0.16 0.72% -59.98%
Alnylam Pharmaceuticals 126.91 2.04 1.63% -6.61%
Amgen 245.24 -0.11 -0.04% -1.36%
BioCryst Pharmaceuticals 8.62 0.12 1.41% -40.06%
Biogen 200.69 -2.21 -1.09% -28.77%
Bluebird Bio 3.59 0.20 5.75% -88.31%
BioMarin Pharmaceutical 77.90 0.58 0.75% 0.72%
Bristol-Myers Squibb 78.01 -0.21 -0.27% 19.01%
ChemoCentryx 20.04 0.84 4.38% 93.44%
Clovis Oncology 0.78 0 0% -85.77%
CTI Biopharma 4.50 0.10 2.27% 100.00%
Exelixis 20.50 -0.19 -0.92% -15.78%
Gilead Sciences 63.36 0.18 0.28% -7.51%
Intercept Pharmaceuticals 18.51 -0.31 -1.65% 6.50%
Idera Pharmaceuticals 0.41 -0.0001 -0.02% -61.33%
Incyte Corp 74.08 -1.43 -1.89% -9.34%
Ionis Pharmaceuticals 38.50 -0.26 -0.66% 4.41%
Eli Lilly 296.80 -4.60 -1.53% 51.03%
MacroGenics 4.08 -0.24 -5.45% -86.76%
Merck & Co 92.69 -0.31 -0.33% 16.80%
Moderna Inc 141.77 -0.51 -0.36% -10.27%
Mirati Therapeutics 58.40 -1.60 -2.66% -62.68%
Neurocrine Biosciences 85.71 -0.09 -0.10% -8.63%
Nektar Therapeutics 3.80 -0.15 -3.68% -79.07%
Lumos Pharma Inc. 7.63 -0.05 -0.65% -26.42%
Novartis 87.80 0.39 0.45% 10.14%
Novartis 87.82 -0.10 -0.11% -0.99%
Puma Biotechnology 1.99 -0.01 -0.50% -80.41%
Pfizer 50.76 -0.59 -1.14% 27.43%
PTC Therapeutics 31.16 -0.69 -2.17% -18.54%
Ultragenyx Pharmaceutical 51.67 -2.68 -4.93% -53.63%
Regeneron Pharmaceuticals 663.60 -3.96 -0.59% 30.05%
Seattle Genetics 143.70 -2.85 -1.94% -3.06%
Sarepta Therapeutics 69.57 2.04 3.02% -7.40%
Vertex Pharmaceuticals 257.90 -3.94 -1.50% 20.49%

Indexes Price Day Year
USND 11792 -192.86 -1.61% -11.34%
US500 4023 -66.09 -1.62% -2.26%
USNDX 12335 -228.74 -1.82% -6.82%

Incyte Corp
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.